Table 1.
Demographic, clinical, and MRI data of patients with 6- and 11-year follow-up.
| 6-year FU | Total | Both IT and SC lesions | Only SC lesions | Only IT lesions | No IT nor SC lesions | p value |
|---|---|---|---|---|---|---|
| Baseline | ||||||
| Number of patientsa | 153 | 61 (39.9) | 49 (32.0) | 16 (10.5) | 27 (17.6) | |
| Sex (% female)a | 104 (68.0) | 42 (68.9) | 36 (73.5) | 7 (43.8) | 19 (70.4) | 0.17d |
| Age at onsetb | 34.8 (8.8) | 33.9 (9.6) | 35.0 (8.7) | 35.6 (7.0) | 35.6 (8.3) | 0.81e |
| Disease duration at BLc (months) | 6.0 (4.0–8.0) | 6.0 (3.0–8.5) | 6.0 (4.0–8.5) | 5.0 (4.0–10.0) | 6.0 (4.0–8.0) | 0.91f |
| EDSS BLc | 2.0 (1.5–3.0) | 2.0 (1.8–3.0) | 2.0 (1.0–2.5) | 1.5 (1.5–2.9) | 2.5 (2.0–3.0) | 0.064f |
| TWT BLb | 4.1 (1.2) | 4.1 (1.0) | 4.2 (1.3) | 3.9 (1.6) | 3.9 (0.9) | 0.79e |
| HPT BLb | 18.0 (2.7) | 18.3 (2.9) | 17.8 (2.7) | 17.9 (1.9) | 17.7 (2.5) | 0.68e |
| Onset symptoms (incl. mf) | ||||||
| Optic neuritis | 35 | 15 | 10 | 1 | 9 | |
| Brainstem/posterior fossa | 48 | 22 | 6 | 11 | 9 | |
| Spinal cord | 81 | 31 | 34 | 4 | 12 | |
| Brain | 9 | 4 | 2 | 2 | 1 | |
| Number of patients with mf symptoms | 20 | 11 | 3 | 2 | 4 | |
| MRI measures | ||||||
| SC T2 lesionsc | 1 (0–4) | 3 (1–7) | 2 (1–7) | |||
| SC-enhancing lesionsc | 0 (0–0) | 0 (0–1) | 0 (0–1) | |||
| Infratentorial T2 lesionsc | 0 (0–1) | 2 (1–3) | 1 (1–2) | |||
| Infratentorial T1c lesionsc | 0 (0–0) | 0 (0–0) | 0 (0–0) | |||
| Supratentorial T2 lesionsc | 13 (6–27) | 21 (11–42) | 9 (6–17) | 9 (6–21) | 9 (3–15) | <0.001 f |
| Supratentorial T1c lesionsc | 0 (0–1) | 1 (0–2) | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.003 f |
| FU measurements | ||||||
| FU Y6 (years)b | 5.8 (1.0) | 6.0 (1.0) | 5.9 (0.9) | 5.4 (0.6) | 5.7 (0.9) | 0.093e |
| DMT until Y6 (%)a | 83 (54.2) | 40 (65.6) | 28 (57.1) | 5 (31.3) | 10 (37.0) | 0.019 d |
| EDSS Y6c | 2.0 (1.5–3.5) | 2.5 (1.5–4.0) | 2.0 (2.0–3.0) | 1.8 (1.0–2.9) | 2.0 (1.5–3.5) | 0.25f |
| EDSS ⩾3.0 Y6 (%)a | 59 (38.6) | 27 (44.3) | 17 (34.7) | 4 (25.0) | 11 (40.7) | 0.49d |
| EDSS progression Y6 (%)a | 55 (35.9) | 24 (39.3) | 24 (49.0) | 2 (12.5) | 5 (18.5) | 0.010 d |
| TWT Y6b | 4.3 (1.6) | 4.8 (2.1) | 4.0 (0.6) | 3.5 (0.8) | 4.3 (1.5) | 0.018 e |
| HPT Y6b | 20.0 (12.5) | 19.9 (3.9) | 21.9 (21.6) | 18.1 (2.2) | 17.9 (2.2) | 0.58e |
| EDSS-plus progression Y6 (%)a | 78 (55.7) | 32 (58.2) | 31 (68.9) | 6 (40.0) | 9 (36.0) | 0.033 d |
| 11-year FU | Total | Both IT and SC lesions | Only SC lesions | Only IT lesions | No IT nor SC lesions | p value |
| Baseline | ||||||
| Number of patientsa | 95 | 39 (41.1) | 28 (29.5) | 12 (12.6) | 16 (16.8) | |
| Sex (% female)a | 64 (67.4) | 23 (59.0) | 21 (75.0) | 6 (50.0) | 14 (87.5) | 0.086d |
| Age at onsetb | 35.0 (9.0) | 35.8 (10.2) | 34.4 (9.0) | 36.5 (7.5) | 32.9 (7.0) | 0.67e |
| Disease duration at BLc (months) | 6 (4–8) | 6.0 (4.0–9.0) | 6.0 (5.0–9.0) | 4.0 (4.0–6.0) | 6.0 (4.0–7.0) | 0.48f |
| EDSS BLc | 2.0 (1.5–3.0) | 2.0 (1.5–3.0) | 1.5 (1.0–2.5) | 1.8 (1.5–2.9) | 2.5 (1.1–3.0) | 0.15f |
| TWT BLb | 4.1 (1.1) | 4.1 (1.0) | 4.1 (1.0) | 4.1 (1.7) | 4.0 (1.0) | 0.99e |
| HPT BLb | 17.9 (2.5) | 18.3 (2.8) | 17.2 (1.6) | 18.3 (1.9) | 18.0 (3.0) | 0.33e |
| Onset symptoms (incl. mf) | ||||||
| Optic neuritis | 22 | 8 | 8 | 1 | 5 | |
| Brainstem/posterior fossa | 29 | 12 | 6 | 7 | 4 | |
| Spinal cord | 50 | 22 | 16 | 3 | 9 | |
| Brain | 8 | 3 | 1 | 3 | 1 | |
| Number of patients with mf symptoms | 14 | 6 | 3 | 2 | 3 | |
| MRI measures | ||||||
| SC T2 lesionsc | 1 (0–4) | 3 (1–6) | 2 (1–4) | |||
| SC-enhancing lesionsc | 0 (0–0) | 0 (0–0) | 0 (0–1) | |||
| Infratentorial T2 lesionsc | 1 (0–1) | 2 (1–3) | 1 (1–1) | |||
| Infratentorial T1c lesionsc | 0 (0–0) | 0 (0–0) | 0 (0–0) | |||
| Supratentorial T2 lesionsc | 13 (7–30) | 24 (11–42) | 11 (7–19) | 9 (6–21) | 8 (3–14) | <0.001 f |
| Supratentorial T1c lesionsc | 0 (0–2) | 1 (0–2) | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.039 f |
| FU measurements | ||||||
| FU Y11 (years)b | 11.4 (1.8) | 11.5 (1.9) | 11.0 (1.8) | 11.3 (1.6) | 11.8 (1.5) | 0.49e |
| DMT until Y11 (%)a | 63 (66.3) | 29 (74.4) | 21 (75.0) | 6 (50.0) | 7 (43.8) | 0.067d |
| EDSS Y11c | 3.0 (2.0–4.0) | 3.5 (2.5–4.0) | 3.0 (2.1–3.0) | 1.8 (1.1–2.9) | 3.0 (1.6–4.0) | 0.012 f |
| EDSS ⩾3.0 Y11 (%)a | 55 (57.9) | 25 (64.1) | 18 (64.3) | 3 (25.0) | 9 (56.3) | 0.092d |
| EDSS progression Y11 (%)a | 51 (53.7) | 23 (59.0) | 18 (64.3) | 1 (8.3) | 9 (56.3) | 0.009 d |
| TWT Y11b | 5.5 (5.6) | 6.9 (8.9) | 4.5 (1.0) | 4.1 (0.9) | 4.8 (1.4) | 0.26e |
| HPT Y11b | 20.2 (4.0) | 21.5 (5.3) | 19.1 (2.2) | 19.2 (2.2) | 19.8 (3.3) | 0.058e |
| EDSS-plus progression Y11 (%)a | 63 (69.2) | 27 (73.0) | 19 (70.4) | 5 (45.5) | 12 (75.0) | 0.33d |
FU: follow-up; IT: infratentorial; SC: spinal cord; EDSS: Expanded Disability Status Scale; BL: baseline; TWT: 25-foot walk test; HPT: 9-hole peg test; mf: multifocal; MRI: magnetic resonance imaging; T2 lesions: T2-hyperintense lesions; T1c: T1-gadolinium-enhancing lesions; DMT: disease-modifying treatment; Y: year.
Number and percentage.
Mean (standard deviation).
Median (interquartile range).
Pearson’s chi square.
Independent-samples t test
Mann–Whitney U test.
Table 1 shows the demographic, clinical and imaging of all patients (left column) and separate for the four groups based on the presence of infratentorial and/or spinal cord lesions at the baseline MRI. Information is shown for patients with a 6-year FU (all patients, upper part) and patients with also an 11-year FU (lower part). The MRI measures are presented as the median of lesion number and the interquartile range. For example, patients with 6-year FU and only spinal cord lesions (without infratentorial lesions) had a median of nine supratentorial T2 lesions with a interquartile range of 6–17. The p values in the right column represent the differences between the four groups calculated using the indicated statistical tests. Level of significance was set at p 0.05 (bold).